Fig. 3From: Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in ChinaMonte Carlo simulation scatters plot in probabilistic sensitivity analyses of the PEACE study population. (A and B) are the results from the Chinese healthcare perspective, C and D are the results from the Chinese private payer perspectiveThe dotted line shows the willingness-to-pay threshold, with a slope of CNY 257094 per quality-adjusted life-year gained. CNY, Chinese yuan; QALY, quality-adjusted life-year; WTP, willingness-to-payBack to article page